Form 8-K - Current report:
SEC Accession No. 0001140361-23-012083
Filing Date
2023-03-16
Accepted
2023-03-16 17:00:38
Documents
13
Period of Report
2023-03-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K brhc10049884_8k.htm   iXBRL 8-K 33742
  Complete submission text file 0001140361-23-012083.txt   216895

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20230313.xsd EX-101.SCH 4369
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE roiv-20230313_def.xml EX-101.DEF 18158
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20230313_lab.xml EX-101.LAB 28149
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20230313_pre.xml EX-101.PRE 20400
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10049884_8k_htm.xml XML 6547
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 23739622
SIC: 2834 Pharmaceutical Preparations